The ruling means that small-scale compounders must immediately stop making their versions of Novo’s Ozempic and Wegovy, while ...

Patients flocked to those Ozempic, Wegovy copycats when the branded drugs were in short supply, or if they didn’t have ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment Wegovy, Novo Nordisk has ... of oral semaglutide lost 15% of their ...

However, making it will require Novo Nordisk to ramp up semaglutide production even further. Citing a Novo spokesperson, pharmaceuticals news site BioPharmaDive reported yesterday that Novo ...

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, ...

They are large molecule drugs, so complex in structure and must be ... manner as these market-leading products. Novo Nordisk offers a pill version of semaglutide, called Rybelsus, for type 2 ...